Protalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock

Protalix BioTherapeutics Announces the Pricing of Public

Offering of Common Stock

CARMIEL, Israel, February 16, 2012 /PR

Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), announced today the pricing of its previously announced

underwritten public offering of 4.5 million shares of its common stock at a price to the public of $5.25 per share. The

Company has granted the underwriters a 30-day option to purchase up to an aggregate of 675,000 additional shares of common

stock to cover over-allotments, if any. The offering is expected to settle and close on February 22, 2012, subject to

customary closing conditions. Jefferies & Company, Inc. is acting as the sole book-running manager and each of Canaccord

Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. The Company expects to use the net

proceeds from the sale of the shares primarily to fund clinical trials for the Company's product candidates, to fund

the Company's research and development activities, to enhance the Company's manufacturing capacity, for working

capital and general corporate purposes.

is being made pursuant to an effective shelf registration statement. Before you invest, you should read the base prospectus in

such shelf registration statement, the preliminary prospectus supplement and other documents the Company has filed with the U.S.

Securities and Exchange Commission, or the SEC, for more complete information about the Company and this offering. The offering

may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending

a request to the offices of Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,

12th Floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com. Alternatively,

you may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell,

or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or

other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under

the securities laws of any such state or other jurisdiction.

Protalix is a biopharmaceutical company focused on the development

and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system,

Forward Looking Statements

To the extent that statements in this press release are

not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private

Securities Litigation Reform Act of 1995. The terms "anticipate," "believe," "estimate," "expect"

and "intend" and other words or phrases of similar import are intended to identify forward-looking statements. These

forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and

results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to

such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences

include, among others: risks relating to our ability to complete the proposed offering in a timely manner, if at all; risks relating

to the sufficiency of the funds raised in the proposed offering, if any; risks relating to our use of the net proceeds from the

proposed offering; risks relating to the review process of the FDA, the European Medicines Agency, or the EMA, other foreign regulatory

bodies and other governmental regulatory bodies, including the risk that regulatory authorities may find that the data from our

clinical trials and other studies is insufficient for regulatory approval; risks relating to delays in the FDA's, the EMA's or

other foreign regulatory authorities' approval of any applications we file or refusals to approve such filings, including the

NDA we filed with the FDA for taliglucerase alfa for the treatment of Gaucher disease; the risk that applicable regulatory authorities

may refuse to approve the marketing and sale of a drug product even after acceptance of an application we file for the drug product;

risks relating to potential restrictions on the marketing and sale of certain of our product candidates in certain territories

due to the orphan drug status that may be granted to competing products, including the risk that the orphan drug designation granted

by the EMA to VPRIV in the European Union may prevent the marketing of taliglucerase alfa, our lead product candidate,

in the European Union; risks relating to the completion of our clinical trials; and other factors described in our filings with

the SEC. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage

clinical trials, even after obtaining promising earlier trial results or in preliminary findings for such clinical trials. Further,

even if favorable testing data is generated from clinical trials of drug products, the FDA, EMA or any other foreign regulatory

authority may not accept or approve an NDA filed by a pharmaceutical or biotechnology company for such drug product. Failure to

obtain approval from the FDA, EMA or any other foreign regulatory authority of any of our drug candidates in a timely manner,

if at all, will severely undermine our business and results of operations by reducing our potential marketable products and our

ability to generate corresponding product revenues. The statements in this release are valid only as of the date hereof and we

disclaim any obligation to update this information.

The Trout Group, LLC